The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension

References

• Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2012;122:4306–4313.
   PubMed Web of Science ®Google Scholar
• Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol. 2008;44:14–30.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4:306–322.
   PubMed Web of Science ®Google Scholar
• Lau EMT, Giannoulatou E, Celermajer DS, et al. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol. 2017;14:603–614.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Montani D, Celermajer DS, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34.
   PubMed Web of Science ®Google Scholar
• Girerd B, Lau E, Montani D, et al. Genetics of pulmonary hypertension in the clinic. Curr Opin Pulm Med. 2017;23:386–391.
   PubMed Web of Science ®Google Scholar
• Austin ED, Loyd JE. The genetics of pulmonary arterial hypertension. Circ Res. 2014;115:189–202.
   PubMed Web of Science ®Google Scholar
• D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115:343–349.
   PubMed Web of Science ®Google Scholar
• Pullamsetti SS, Savai R, Seeger W, et al. Translational advances in the field of pulmonary hypertension. from cancer biology to new pulmonary arterial hypertension therapeutics. targeting cell growth and proliferation signaling hubs. Am J Respir Crit Care Med. 2017;195:425–437.
   PubMed Web of Science ®Google Scholar
• Boucherat O, Vitry G, Trinh I, et al. The cancer theory of pulmonary arterial hypertension. Pulm Circ. 2017;7:285–299.
   PubMed Web of Science ®Google Scholar
• Rai PR, Cool CD, King JA, et al. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178:558–564.
   PubMed Web of Science ®Google Scholar
• Stenmark KR, Tuder RM, El Kasmi KC. Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension. J Appl Physiol Bethesda Md 1985. 2015;119:1164–1172.
   PubMed Web of Science ®Google Scholar
• D’Alessandro A, El Kasmi KC, Plecitá-Hlavatá L, et al. Hallmarks of pulmonary hypertension: mesenchymal and inflammatory cell metabolic reprogramming. Antioxid Redox Signal. 2018;28:230–250.
   PubMed Web of Science ®Google Scholar
• Cottrill KA, Chan SY. Metabolic dysfunction in pulmonary hypertension: the expanding relevance of the Warburg effect. Eur J Clin Invest. 2013;43:855–865.
   PubMed Web of Science ®Google Scholar
• Plecitá-Hlavatá L, Tauber J, Li M, et al. Constitutive reprogramming of fibroblast mitochondrial metabolism in pulmonary hypertension. Am J Respir Cell Mol Biol. 2016;55:47–57.
   PubMed Web of Science ®Google Scholar
• Archer SL, Fang Y-H, Ryan JJ, et al. Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. Pulm Circ. 2013;3:144–152.
   PubMed Web of Science ®Google Scholar
• Ryan JJ, Archer SL. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res. 2014;115:176–188.
   PubMed Web of Science ®Google Scholar
• Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27:441–464.
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell. 2017;168:657–669.
   PubMed Web of Science ®Google Scholar
• Zhang J, Pavlova NN, Thompson CB. Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine. Embo J. 2017;36:1302–1315.
   PubMed Web of Science ®Google Scholar
• Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123:3678–3684.
   PubMed Web of Science ®Google Scholar
• Bertero T, Oldham WM, Cottrill KA, et al. Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. J Clin Invest. 2016;126:3313–3335.
   PubMed Web of Science ®Google Scholar
• Egnatchik RA, Brittain EL, Shah AT, et al. Dysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertension. Pulm Circ. 2017;7:186–199.
   PubMed Web of Science ®Google Scholar
• Bergström J, Fürst P, Norée LO, et al. Intracellular free amino acid concentration in human muscle tissue. J Appl Physiol. 1974;36:693–697.
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Perriello G, Meyer C, et al. Role of glutamine in human carbohydrate metabolism in kidney and other tissues. Kidney Int. 1999;55:778–792.
   PubMed Web of Science ®Google Scholar
• Felig P, Wahren J, Räf L. Evidence of inter-organ amino-acid transport by blood cells in humans. Proc Natl Acad Sci U S A. 1973;70:1775–1779.
   PubMed Web of Science ®Google Scholar
• Tischler ME, Goldberg AL. Leucine degradation and release of glutamine and alanine by adipose tissue. J Biol Chem. 1980;255:8074–8081.
   PubMed Web of Science ®Google Scholar
• Patterson BW, Horowitz JF, Wu G, et al. Regional muscle and adipose tissue amino acid metabolism in lean and obese women. Am J Physiol Endocrinol Metab. 2002;282:E931–936.
   PubMed Web of Science ®Google Scholar
• Dudrick PS, Inoue Y, Espat NJ, et al. Na(+)-dependent glutamine transport in the liver of tumour-bearing rats. Surg Oncol. 1993;2:205–215.
   PubMed Web of Science ®Google Scholar
• Souba WW, Herskowitz K, Plumley DA. Lung glutamine metabolism. JPEN J Parenter Enteral Nutr. 1990;14:68S–70S.
   PubMed Web of Science ®Google Scholar
• Lacey JM, Wilmore DW. Is glutamine a conditionally essential amino acid? Nutr Rev. 1990;48:297–309.
   PubMed Web of Science ®Google Scholar
• Hosios AM, Hecht VC, Danai LV, et al. Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells. Dev Cell. 2016;36:540–549.
   PubMed Web of Science ®Google Scholar
• Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16:619–634.
   PubMed Web of Science ®Google Scholar
• Koppula P, Zhang Y, Zhuang L, et al. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun. 2018;38:12.
   PubMed Web of Science ®Google Scholar
• Matés JM, Segura JA, Martín-Rufián M, et al. Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Curr Mol Med. 2013;13:514–534.
   PubMed Web of Science ®Google Scholar
• Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458:762–765.
   PubMed Web of Science ®Google Scholar
• Gross MI, Demo SD, Dennison JB, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014;13:890–901.
   PubMed Web of Science ®Google Scholar
• Wang J-B, Erickson JW, Fuji R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010;18:207–219.
   PubMed Web of Science ®Google Scholar
• Matés JM, Campos-Sandoval JA, Márquez J. Glutaminase isoenzymes in the metabolic therapy of cancer. Biochim Biophys Acta Rev Cancer. 2018. DOI:10.1016/j.bbcan.2018.07.007
   PubMed Web of Science ®Google Scholar
• Loscalzo J. Redox dysregulation in vascular pathobiology. Free Radic Biol Med. 2014;75(Suppl 1):S2.
   PubMedGoogle Scholar
• Panieri E, Santoro MM. ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis. 2016;7:e2253.
   PubMed Web of Science ®Google Scholar
• Culley MK, Chan SY. Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains. J Clin Invest. 2018;128:3704–3715.
   PubMed Web of Science ®Google Scholar
• Jin L, Li D, Alesi GN, et al. Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. Cancer Cell. 2015;27:257–270.
   PubMed Web of Science ®Google Scholar
• Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 2015;17:351–359.
   PubMed Web of Science ®Google Scholar
• Xiao W, Wang RS, Handy DE, et al. NAD(H) and NADP(H) redox couples and cellular energy metabolism. Antioxid Redox Signal. 2018;28:251–272.
   PubMed Web of Science ®Google Scholar
• Fessel JP, Oldham WM. Pyridine dinucleotides from molecules to man. Antioxid Redox Signal. 2018;28:180–212.
   PubMed Web of Science ®Google Scholar
• Tardito S, Oudin A, Ahmed SU, et al. Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat Cell Biol. 2015;17:1556–1568.
   PubMed Web of Science ®Google Scholar
• Lane AN, Fan TWM. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res. 2015;43:2466–2485.
   PubMed Web of Science ®Google Scholar
• Birsoy K, Wang T, Chen WW, et al. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell. 2015;162:540–551.
   PubMed Web of Science ®Google Scholar
• Cardaci S, Zheng L, MacKay G, et al. Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. Nat Cell Biol. 2015;17:1317–1326.
   PubMed Web of Science ®Google Scholar
• Garcia-Bermudez J, Baudrier L, La K, et al. Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumors. Nat Cell Biol. 2018;20:775–781.
   PubMed Web of Science ®Google Scholar
• Sullivan LB, Gui DY, Hosios AM, et al. Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells. Cell. 2015;162:552–563.
   PubMed Web of Science ®Google Scholar
• Sullivan LB, Luengo A, Danai LV, et al. Aspartate is an endogenous metabolic limitation for tumor growth. Nat Cell Biol. 2018;20:782–788.
   PubMed Web of Science ®Google Scholar
• Ben-Sahra I, Howell JJ, Asara JM, et al. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science. 2013;339:1323–1328.
   PubMed Web of Science ®Google Scholar
• Ben-Sahra I, Manning BD. mTORC1 signaling and the metabolic control of cell growth. Curr Opin Cell Biol. 2017;45:72–82.
   PubMed Web of Science ®Google Scholar
• Terunuma A, Putluri N, Mishra P, et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest. 2014;124:398–412.
   PubMed Web of Science ®Google Scholar
• Zack TI, Schumacher SE, Carter SL, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013;45:1134–1140.
   PubMed Web of Science ®Google Scholar
• Wise DR, DeBerardinis RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008;105:18782–18787.
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A. 2007;104:19345–19350.
   PubMed Web of Science ®Google Scholar
• Liu W, Le A, Hancock C, et al. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci U S A. 2012;109:8983–8988.
   PubMed Web of Science ®Google Scholar
• Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–854.
   PubMed Web of Science ®Google Scholar
• Bartel DP. Metazoan MicroRNAs. Cell. 2018;173:20–51.
   PubMed Web of Science ®Google Scholar
• Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell. 2012;149:515–524.
   PubMed Web of Science ®Google Scholar
• Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 1 (2018). DOI:10.1038/s41580-018-0045-7
   Web of Science ®Google Scholar
• Rottiers V, Näär AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 2012;13:239–250.
   PubMed Web of Science ®Google Scholar
• Condorelli G, Latronico MVG, Cavarretta E. microRNAs in cardiovascular diseases: current knowledge and the road ahead. J Am Coll Cardiol. 2014;63:2177–2187.
   PubMed Web of Science ®Google Scholar
• Farazi TA, Hoell JI, Morozov P, et al. microRNAs in human cancer. Adv Exp Med Biol. 2013;774:1–20.
   PubMed Web of Science ®Google Scholar
• Csibi A, Lee G, Toon SO, et al. The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation. Curr Biol CB. 2014;24:2274–2280.
   PubMed Web of Science ®Google Scholar
• Craze ML, Cheung H, Jewa N, et al. MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer. Br J Cancer. 2018;2:258–265.
   Google Scholar
• Chen Z, Wang Y, Warden C, et al. Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells. J Steroid Biochem Mol Biol. 2015;149:118–127.
   PubMed Web of Science ®Google Scholar
• Cai Y, Han M, Luo L, et al. Increased expression of PDGF and c-myc genes in lungs and pulmonary arteries of pulmonary hypertensive rats induced by hypoxia. Chin Med Sci J Chung-Kuo Hsueh Ko Hsueh Tsa Chih. 1996;11:152–156.
   Google Scholar
• Ahmad A, Ahmad S, Malcolm KC, et al. Differential regulation of pulmonary vascular cell growth by hypoxia-inducible transcription factor–1α and hypoxia-inducible transcription factor–2α. Am J Respir Cell Mol Biol. 2013;49:78–85.
   PubMed Web of Science ®Google Scholar
• Zhang W-F, Xiong YW, Zhu TT, et al. MicroRNA let-7g inhibited hypoxia-induced proliferation of PASMCs via G0/G1 cell cycle arrest by targeting c-myc. Life Sci. 2017;170:9–15.
   PubMed Web of Science ®Google Scholar
• Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res. 2009;104:236–244, 28p following 244
   PubMed Web of Science ®Google Scholar
• Maston LD, Jones DT, Giermakowska W, et al. Interleukin-6 trans-signaling contributes to chronic hypoxia-induced pulmonary hypertension. Pulm Circ. 2018;8:2045894018780734.
   Web of Science ®Google Scholar
• Savale L, Tu L, Rideau D, et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res. 2009;10:6.
   PubMed Web of Science ®Google Scholar
• Negi V, Chan SY. Discerning functional hierarchies of microRNAs in pulmonary hypertension. JCI Insight. 2017;2:e91327.
   PubMed Web of Science ®Google Scholar
• Wei C, Henderson H, Spradley C, et al. Circulating miRNAs as potential marker for pulmonary hypertension. PloS One. 2013;8:e64396.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Peng B, Han Y. MiR-23a regulates the proliferation and migration of human pulmonary artery smooth muscle cells (HPASMCs) through targeting BMPR2/Smad1 signaling. Biomed Pharmacother Biomed Pharmacother. 2018;103:1279–1286.
   PubMed Web of Science ®Google Scholar
• Weinberg F, Hamanaka R, Wheaton WW, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A. 2010;107:8788–8793.
   PubMed Web of Science ®Google Scholar
• Gaglio D, Soldati C, Vanoni M, et al. Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. PloS One. 2009;4:e4715.
   PubMed Web of Science ®Google Scholar
• Brunelli L, Caiola E, Marabese M, et al. Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells. Oncotarget. 2014;5:4722–4731.
   PubMedGoogle Scholar
• Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496:101–105.
   PubMed Web of Science ®Google Scholar
• Pullamsetti SS, Kojonazarov B, Storn S, et al. Lung cancer-associated pulmonary hypertension: role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. Sci Transl Med. 2017;9:eaai9048.
   PubMed Web of Science ®Google Scholar
• Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 2014;14:359–370.
   PubMed Web of Science ®Google Scholar
• Jiang L, Shestov AA, Swain P, et al. Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature. 2016;532:255–258.
   PubMed Web of Science ®Google Scholar
• Hu W, Zhang C, Wu R, et al. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A. 2010;107:7455–7460.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Tanaka T, Poyurovsky MV, et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A. 2010;107:7461–7466.
   PubMed Web of Science ®Google Scholar
• Mizuno S, Bogaard HJ, Kraskauskas D, et al. p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. Am J Physiol Lung Cell Mol Physiol. 2011;300:L753–761.
   PubMed Web of Science ®Google Scholar
• Jacquin S, Rincheval V, Mignotte B, et al. Inactivation of p53 is sufficient to induce development of pulmonary hypertension in rats. PloS One. 2015;10:e0131940.
   PubMed Web of Science ®Google Scholar
• Mouraret N, Marcos E, Abid S, et al. Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension. Circulation. 2013;127:1664–1676.
   PubMed Web of Science ®Google Scholar
• Metallo CM, Gamiero PA, Bell EL, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2012;481:380–384.
   PubMed Web of Science ®Google Scholar
• Sun RC, Denko NC. Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab. 2014;19:285–292.
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Lum JJ, Hatzivassiliou G, et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11–20.
   PubMed Web of Science ®Google Scholar
• Gameiro PA, Yang J, Metelo AM, et al. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab. 2013;17:372–385.
   PubMed Web of Science ®Google Scholar
• Le A, Lane AN, Hamaker M, et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012;15:110–121.
   PubMed Web of Science ®Google Scholar
• Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011;12:9–22.
   PubMed Web of Science ®Google Scholar
• Nakazawa MS, Keith B, Simon MC. Oxygen availability and metabolic adaptations. Nat Rev Cancer. 2016;16:663–673.
   PubMed Web of Science ®Google Scholar
• Ryan J, Bloch K, Archer SL. Rodent models of pulmonary hypertension: harmonisation with the world health organisation’s categorisation of human PH. Int J Clin Pract Suppl. 2011;65:15–34.
   Google Scholar
• Yu AY, Shimoda LA, Iyer NV, et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1α. J Clin Invest. 1999;103:691–696.
   PubMed Web of Science ®Google Scholar
• Ball MK, Waypa GB, Mungai PT, et al. Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1α. Am J Respir Crit Care Med. 2013;189:314–324.
   Web of Science ®Google Scholar
• Kapitsinou PP, Rajendran G, Astleford L, et al. The endothelial PHD2/HIF-2 axis regulates pulmonary artery pressure in mice. Mol Cell Biol. 2016;36:1584–1594.
   PubMed Web of Science ®Google Scholar
• Hickey MM, Richardson T, Wang T, et al. The von Hippel–lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. J Clin Invest. 2010;120:827–839.
   PubMed Web of Science ®Google Scholar
• Kapitsinou PP, Rajendran G, Astleford L, et al. The endothelial prolyl-4-hydroxylase domain 2/hypoxia-inducible factor 2 axis regulates pulmonary artery pressure in mice. Mol Cell Biol. 2016;36:1584–1594.
   PubMed Web of Science ®Google Scholar
• Chan SY, Loscalzo J. MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle Georget Tex. 2010;9:1072–1083.
   PubMed Web of Science ®Google Scholar
• Chan SY, Zhang YY, Hemann C, et al. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab. 2009;10:273–284.
   PubMed Web of Science ®Google Scholar
• Bertero T, Rezzonico R, Pottier N, et al. Impact of MicroRNAs in the cellular response to hypoxia. Int Rev Cell Mol Biol. 2017;333:91–158.
   PubMed Web of Science ®Google Scholar
• Bertero T, Robbe-Sermensant K, Le Brigand K, et al. MicroRNA target identification: lessons from hypoxamiRs. Antioxid Redox Signal. 2014;21:1249–1268.
   PubMed Web of Science ®Google Scholar
• White K, Lu Y, Annis S, et al. Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension. EMBO Mol Med. 2015;7:695–713.
   PubMed Web of Science ®Google Scholar
• Favaro E, Ramachandran A, McCormick R, et al. MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PloS One. 2010;5:e10345.
   PubMed Web of Science ®Google Scholar
• Puisségur M-P, Mazure NM, Bertero T, et al. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ. 2011;18:465–478.
   PubMed Web of Science ®Google Scholar
• Grosso S, Doyen J, Parks SK, et al. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis. 2013;4:e544.
   PubMed Web of Science ®Google Scholar
• Fasanaro P, Greco S, Lorenzi M, et al. An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem. 2009;284:35134–35143.
   PubMed Web of Science ®Google Scholar
• Huang X, Ding L, Bennewith KL, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell. 2009;35:856–867.
   PubMed Web of Science ®Google Scholar
• Evans JDW, Girerd B, Montani D, et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med. 2016;4:129–137.
   PubMed Web of Science ®Google Scholar
• Guignabert C, Bailly S, Humbert M. Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations. Expert Opin Ther Targets. 2017;21:181–190.
   PubMed Web of Science ®Google Scholar
• Antigny F, Hautefort A, Meloche J, et al. Potassium channel subfamily K member 3 (KCNK3) contributes to the development of pulmonary arterial hypertension. Circulation. 2016;133:1371–1385.
   PubMed Web of Science ®Google Scholar
• Ma L, Roman-Campos D, Austin ED, et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med. 2013;369:351–361.
   PubMed Web of Science ®Google Scholar
• Gräf S, Haimel M, Bleda M, et al. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat Commun. 2018;9:1416.
   PubMed Web of Science ®Google Scholar
• Bernard K, Logsdon NJ, Benavides GA, et al. Glutaminolysis is required for transforming growth factor-β1-induced myofibroblast differentiation and activation. J Biol Chem. 2018;293:1218–1228.
   PubMed Web of Science ®Google Scholar
• Soukupova J, Malfettone A, Hyroššová P, et al. Role of the transforming growth factor-β in regulating hepatocellular carcinoma oxidative metabolism. Sci Rep. 2017;7:12486.
   PubMed Web of Science ®Google Scholar
• Guo Y, Deng Y, Li X, et al. Glutaminolysis was induced by TGF-β1 through PP2Ac regulated Raf-MEK-ERK signaling in endothelial cells. PLoS ONE. 2016;11:e0162658.
   PubMed Web of Science ®Google Scholar
• Bertero T, Handen AL, Chan SY. Factors associated with heritable pulmonary arterial hypertension exert convergent actions on the miR-130/301-vascular matrix feedback loop. Int J Mol Sci. 2018;19:2289.
   Web of Science ®Google Scholar
• Bertero T, Oldham WM, Grasset EM, et al. Tumor-stroma mechanics coordinate amino acid availability to sustain tumor growth and malignancy. Cell Metab. 2018;29:124–140.
   PubMed Web of Science ®Google Scholar
• Harding HP, Zhang Y, Zeng H, et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell. 2003;11:619–633.
   PubMed Web of Science ®Google Scholar
• Jewell JL, Guan K-L. Nutrient signaling to mTOR and cell growth. Trends Biochem Sci. 2013;38:233–242.
   PubMed Web of Science ®Google Scholar
• Pouysségur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441:437–443.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148:399–408.
   PubMed Web of Science ®Google Scholar
• Bertero T, Cottrill KA, Lu Y, et al. Matrix remodeling promotes pulmonary hypertension through feedback mechanoactivation of the YAP/TAZ-miR-130/301 circuit. Cell Rep. 2015;13:1016–1032.
   PubMed Web of Science ®Google Scholar
• Rabinovitch M, Guignabert C, Humbert M, et al. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res. 2014;115:165–175.
   PubMed Web of Science ®Google Scholar
• Pullamsetti SS, Savai R. Macrophage regulation during vascular remodeling: implications for pulmonary hypertension therapy. Am J Respir Cell Mol Biol. 2017;56:556–558.
   PubMed Web of Science ®Google Scholar
• Korniszewski L, Kurzyna M, Stolarki B, et al. Fatal primary pulmonary hypertension in a 30-yr-old female with APECED syndrome. Eur Respir J. 2003;22:709–711.
   PubMed Web of Science ®Google Scholar
• Goveia J, Stapor P, Carmeliet P. Principles of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in disease. EMBO Mol Med. 2014;6:1105–1120.
   PubMed Web of Science ®Google Scholar
• Kominsky DJ, Campbell EL, Colgan SP. Metabolic shifts in immunity and inflammation. J Immunol Baltim Md 1950. 2010;184:4062–4068.
   Google Scholar
• Deidda M, Piras C, Cadeddu Dessalvi C, et al. Distinctive metabolomic fingerprint in scleroderma patients with pulmonary arterial hypertension. Int J Cardiol. 2017;241:401–406.
   PubMed Web of Science ®Google Scholar
• Fernández-Ochoa Á, Quirantes-Piné R, Borrás-Linares I, et al. Urinary and plasma metabolite differences detected by HPLC-ESI-QTOF-MS in systemic sclerosis patients. J Pharm Biomed Anal. 2018;162:82–90.
   PubMed Web of Science ®Google Scholar
• Li JV, Holmes E, Saric J, et al. Metabolic profiling of a Schistosoma mansoni infection in mouse tissues using magic angle spinning-nuclear magnetic resonance spectroscopy. Int J Parasitol. 2009;39:547–558.
   PubMed Web of Science ®Google Scholar
• Hegedus A, Kavanagh Williamson M, Huthoff H. HIV-1 pathogenicity and virion production are dependent on the metabolic phenotype of activated CD4+ T cells. Retrovirology. 2014;11:98.
   PubMed Web of Science ®Google Scholar
• Hegedus A, Kavanagh Williamson M, Khan MB, et al. Evidence for altered glutamine metabolism in human immunodeficiency virus type 1 infected primary human CD4+ T cells. AIDS Res Hum Retroviruses. 2017;33:1236–1247.
   PubMed Web of Science ®Google Scholar
• Wu B, Liu J, Zhao R, et al. Glutaminase 1 regulates the release of extracellular vesicles during neuroinflammation through key metabolic intermediate alpha-ketoglutarate. J Neuroinflammation. 2018;15:79.
   PubMed Web of Science ®Google Scholar
• Zhao J, Lopez AL, Erichsen D, et al. Mitochondrial glutaminase enhances extracellular glutamate production in HIV-1-infected macrophages: linkage to HIV-1 associated dementia. J Neurochem. 2004;88:169–180.
   PubMed Web of Science ®Google Scholar
• Porcheray F, Léone C, Samah B, et al. Glutamate metabolism in HIV-infected macrophages: implications for the CNS. Am J Physiol Cell Physiol. 2006;291:C618–626.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhao L, Jia B, et al. Glutaminase dysregulation in HIV-1-infected human microglia mediates neurotoxicity: relevant to HIV-1-associated neurocognitive disorders. J Neurosci Off J Soc Neurosci. 2011;31:15195–15204.
   PubMed Web of Science ®Google Scholar
• Datta PK, Deshmane S, Khalili K, et al. Glutamate metabolism in HIV-1 infected macrophages: role of HIV-1 Vpr. Cell Cycle Georget Tex. 2016;15:2288–2298.
   PubMed Web of Science ®Google Scholar
• Florentin J, Coppin E, Vasamsetti SB, et al. Inflammatory macrophage expansion in pulmonary hypertension depends upon mobilization of blood-borne monocytes. J Immunol Baltim Md 1950. 2018;200:3612–3625.
   Google Scholar
• Dabral S, Pullamsetti SS, Stiffness V. Mechanotransduction: back in the limelight. Am J Respir Crit Care Med. 2017;196:527–530.
   PubMed Web of Science ®Google Scholar
• Schäfer M, Myers C, Brown RD, et al. Pulmonary arterial stiffness: toward a new paradigm in pulmonary arterial hypertension pathophysiology and assessment. Curr Hypertens Rep. 2016;18:4.
   PubMed Web of Science ®Google Scholar
• Sun W, Chan SY. Pulmonary arterial stiffness: an early and pervasive driver of pulmonary arterial hypertension. Front Med. 2018;5:204.
   Web of Science ®Google Scholar
• Chemla D, Weatherald J, Lau EMT, et al. Clinical and hemodynamic correlates of pulmonary arterial stiffness in incident, untreated patients with idiopathic pulmonary arterial hypertension. Chest. 2018;154:882–892.
   PubMed Web of Science ®Google Scholar
• Panciera T, Azzolin L, Cordenonsi M, et al. Mechanobiology of YAP and TAZ in physiology and disease. Nat Rev Mol Cell Biol. 2017;18:758–770.
   PubMed Web of Science ®Google Scholar
• Halder G, Dupont S, Piccolo S. Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat Rev Mol Cell Biol. 2012;13:591–600.
   PubMed Web of Science ®Google Scholar
• Yu F-X, Zhao B, Guan K-L. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015;163:811–828.
   PubMed Web of Science ®Google Scholar
• Calvo F, Ege N, Grande-Garcia A, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013;15:637–646.
   PubMed Web of Science ®Google Scholar
• Bertero T, Cottrill KA, Annis S, et al. A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions. Sci Rep. 2015;5:18277.
   PubMed Web of Science ®Google Scholar
• Bertero T, Lu Y, Annis S, et al. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. J Clin Invest. 2014;124:3514–3528.
   PubMed Web of Science ®Google Scholar
• Lyssiotis CA, Kimmelman AC. Metabolic Interactions in the Tumor Microenvironment. Trends Cell Biol. 2017;27:863–875.
   PubMed Web of Science ®Google Scholar
• Humbert M, Montani D, Perros F, et al. Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. Vascul Pharmacol. 2008;49:113–118.
   PubMed Web of Science ®Google Scholar
• Naeije R, Manes A. The right ventricle in pulmonary arterial hypertension. Eur Respir Rev Off J Eur Respir Soc. 2014;23:476–487.
   PubMedGoogle Scholar
• Noordegraaf AV, Galiè N. The role of the right ventricle in pulmonary arterial hypertension. Eur Respir Rev. 2011;20:243–253.
   PubMedGoogle Scholar
• Hautefort A, Mendes-Ferreira P, Sabourin J, et al. Bmpr2 mutant rats develop pulmonary and cardiac characteristics of pulmonary arterial hypertension. Circulation. 2018;139:932–948.
   Web of Science ®Google Scholar
• Legchenko E, Chouvarine P, Borchert P, et al. PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Sci Transl Med. 2018;10:eaao0303.
   PubMed Web of Science ®Google Scholar
• Yang T, Wang L, Xiong CM, et al. The ratio of (18)F-FDG activity uptake between the right and left ventricle in patients with pulmonary hypertension correlates with the right ventricular function. Clin Nucl Med. 2014;39:426–430.
   PubMed Web of Science ®Google Scholar
• Graham BB, Kumar R, Mickael C, et al. Severe pulmonary hypertension is associated with altered right ventricle metabolic substrate uptake. Am J Physiol - Lung Cell Mol Physiol. 2015;309:L435–L440.
   PubMed Web of Science ®Google Scholar
• Piao L, Fang YH, Parikh K, et al. Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. J Mol Med Berl Ger. 2013;91:1185–1197.
   PubMed Web of Science ®Google Scholar
• Song M, Kim S-H, Im CY, et al. Recent development of small molecule glutaminase inhibitors. Curr Top Med Chem. 2018;18:432–443.
   PubMed Web of Science ®Google Scholar
• Ahluwalia GS, Grem JL, Hao Z, et al. Metabolism and action of amino acid analog anti-cancer agents. Pharmacol Ther. 1990;46:243–271.
   PubMed Web of Science ®Google Scholar
• Shapiro RA, Clark VM, Curthoys NP. Inactivation of rat renal phosphate-dependent glutaminase with 6-diazo-5-oxo-L-norleucine. Evidence for interaction at the glutamine binding site. J Biol Chem. 1979;254:2835–2838.
   PubMed Web of Science ®Google Scholar
• Robinson MM, McBryant SJ, Tsukamoto T, et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J. 2007;406:407–414.
   PubMed Web of Science ®Google Scholar
• Cassago A, Ferreira AP, Ferreira IM, et al. Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism. Proc Natl Acad Sci U S A. 2012;109:1092–1097.
   PubMed Web of Science ®Google Scholar
• DeLaBarre B, Gross S, Fang C, et al. Full-length human glutaminase in complex with an allosteric inhibitor. Biochemistry (Mosc). 2011;50:10764–10770.
   Google Scholar
• Stalnecker CA, Ulrich SM, Li Y, et al. Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells. Proc Natl Acad Sci U S A. 2015;112:394–399.
   PubMed Web of Science ®Google Scholar
• Hassanein M, Qian J, Hoeksema MD, et al. Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer. Int J Cancer. 2015;137:1587–1597.
   PubMed Web of Science ®Google Scholar
• van Geldermalsen M, Wang Q, Nagarajah R, et al. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene. 2016;35:3201–3208.
   PubMed Web of Science ®Google Scholar
• Schulte ML, Fu A, Zhao P, et al. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Nat Med. 2018;24:194–202.
   PubMed Web of Science ®Google Scholar
• Choi Y-K, Park K-G. Targeting glutamine metabolism for cancer treatment. Biomol Ther. 2018;26:19–28.
   PubMed Web of Science ®Google Scholar
• Korangath P, Teo WW, Sadik H, et al. Targeting glutamine metabolism in breast cancer with aminooxyacetate. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21:3263–3273.
   PubMed Web of Science ®Google Scholar
• Du K, Hyun J, Premont RT, et al. Hedgehog-YAP signaling pathway regulates glutaminolysis to control activation of hepatic stellate cells. Gastroenterology. 2018;154:1465–1479.e13.
   PubMed Web of Science ®Google Scholar